Inotec AMD Limited appoints new CFO/COO

Cambridge, UK – March 2018 – Cambridge based Inotec AMD Limited is pleased to announce the appointment of Justine Brain as its new Chief Financial Officer/Chief Operating Officer.

Inotec AMD is a maker of mobile medical devices designed to heal chronic, hypoxic wounds that afflict millions of sufferers around the world every year. The global wound-care market is projected to grow to $18.3 billion globally in 2019, driven in part by changing life styles and ageing populations in many countries. There are some 400 million diabetes sufferers around the world, some 60 million of whom are likely to develop a lower limb ulcer. As more than 90% of wounds suffer from a lack of oxygen, the launch of NATROX® addresses this serious concern with a simple, cost-effective application which treats a broad spectrum of chronic health problems.

Justine Brain brings to Inotec AMD over 20 years of financial experience with a large proportion of this being within the health care arena including Amgen. Justine has a proven track record in developing world class customer services and process improvements that not only deliver customer satisfaction but cost efficiencies.

Dr Adrian Parton MBE, Chairman of Inotec AMD said “The Board of Directors are pleased to announce the appointment of Justine Brain who started her new role as CFO/COO of the company in March and we believe that her extensive experience will help the Company drive the growth of Inotec AMD’s novel oxygen therapy products on a global basis”.

Ms Brain commented that “I am delighted to join the Inotec AMD team at this exciting time. NATROX® is an excellent product with great potential.”

Inotec continues to develop a world class team and is preparing to launch the product into the United States market during 2018.